Insight

Jun 28, 2024, 14:52

Iván R. González: ICIs in early-stage NSCLC showing promising results

Iván R. González, Medical Oncologist at Comprehensive Oncology Center, Hospital Ángeles Puebla, shared a post on X:

“The inhibition of immune checkpoint points in early-stage NSCLC treatment is showing promising results:

Immunotherapy combined with neoadjuvant chemotherapy significantly improves surgical outcomes and long-term survival.
The combination of immune checkpoint inhibitors and platinum-based chemotherapy is preferred over chemotherapy alone due to lower risk of surgical omission.
Despite advances, the 5-year survival rate remains suboptimal, with many patients experiencing relapse and death from metastatic progression.
Numerous questions persist regarding the optimal strategy, underscoring the need for further research.
Case-by-case discussions in multidisciplinary boards are crucial for addressing challenges and optimizing treatment strategies.

In conclusion immune checkpoint inhibition is transforming early-stage lung cancer treatment, enhancing outcomes and survival. While promising, additional research is needed to address remaining challenges and optimize clinical application.”

Read further.
Source: Iván R. González/X
.

cancer clinical research Comprehensive Oncology Center Hospital Ángeles Puebla Immune Checkpoint Inhibitors immunotherapy Iván R. González long-term survival medical oncologist multidisciplinary approach neoadjuvant chemotherapy non small cell lung cancer NSCLC OncoDaily Oncology platinum-based chemotherapy surgical outcomes Treatment optimization

Faster, Flexible and Affordable: Mikhail Groubman on Building a Global Legacy in Clinical Research in an Untapped Market

Invest in Health Policy: A Conversation with Professor Andreas Charalambous

FDA Approves Cosibelimab-ipdl for Treatment of Metastatic or Locally Advanced Cutaneous Squamous Cell Carcinoma

Dolph Lundgren’s Fight for Life: How He Survived Kidney Cancer After 9 Years of Battle

Agenus and Tanner Pharma Partner to Expand Global Access to BOT/BAL

Special Coverage